Seeking Alpha EN

Coherus outlines $175M annualized LOQTORZI target by 2028 as commercial expansion accelerates

Mar 10, 2026 &03581010202631; 00:58 UTC seekingalpha.com Trending 2/5

Read original on seekingalpha.com ↗

↗

Positive for markets

Sentiment score: +75/100

Moderate impact Medium-term (weeks)

WHAT THIS MEANS

Coherus BioSciences projects $175M in annualized revenue for LOQTORZI by 2028, signaling strong commercial momentum and market expansion potential. This guidance reflects confidence in the drug's market penetration and positions the company for significant revenue growth in the coming years.

AI CONFIDENCE

78% High

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↑

CHRS

CHRSStock

Expected to rise

Positive revenue guidance for LOQTORZI demonstrates successful commercial execution and market acceptance, supporting stock appreciation potential

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Consider accumulating CHRS on any weakness as the $175M revenue target by 2028 provides a clear growth catalyst. Monitor quarterly earnings for progress toward this milestone and any updates on market penetration rates.

KEY SIGNALS

Strong revenue guidance ($175M annualized target)Commercial expansion accelerationProduct market acceptanceMulti-year growth trajectoryImproved financial visibility

SECTORS INVOLVED

HealthcareBiotechnologyPharmaceuticals

Analysis generated on Mar 10, 2026 at 01:04 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Seeking Alpha. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Coherus outlines $175M annualized LOQTORZI target by 2028 as commercial expansion accelerates

RELATED INTELLIGENCE